Probisearch was invited to participate in the 4th Microbiome R&D and Business Collaboration Forum & Probiotics Congress: Europe, held in Amsterdam on 3 – 4 April. The event combined two congresses, focused on the microbiome and probiotics, respectively.
Dr. Esther Jiménez, Probisearch Project Director, featured among the 70 guest speakers and took part in the Probiotics Congress on 3 April. In her presentation, Dr. Jiménez described the results from the randomized, double-blind, placebo-controlled, parallel group trial with 221 healthy full-term infants aged 3 to 12 months. The clinical trial conducted by Probisearch evaluated the safety and tolerability of three probiotic strains owned by multinational company Lallemand. Results showed that all three strains are safe and well tolerated by a healthy infant population. Probisearch researchers also studied the bacterial composition in the gut of participating babies, before and after the trial period, using a mass sequencing technique, as well as their immune profile using a multiplex technology.